Why the study?
Hospitalizations for exacerbations of congestive heart failure, chronic obstructive pulmonary disease, and diabetic ketoacidosis are costly in the United States, prompting the development of machine learning models to predict in-hospital charges.
Can machine learning models accurately predict in-hospital charges for patients admitted with CHF, COPD, or DKA exacerbations?
Can machine learning models accurately predict in-hospital charges for patients admitted with CHF, COPD, or DKA exacerbations?
Machine learning algorithms can accurately predict in-hospital costs for CHF, COPD, and DKA exacerbations using features like age, length of stay, and procedure count.
ML models may aid charge prediction from administrative data; leaves open prospective validation before clinical use.
BACKGROUND: Hospitalizations for exacerbations of congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD) and diabetic ketoacidosis (DKA) are costly in the United States. The purpose of this study was to predict in-hospital charges for each condition using machine learning (ML) models. RESULTS: We conducted a retrospective cohort study on national discharge records of hospitalized adult patients from January 1st, 2016, to December 31st, 2019. We constructed six ML models (linear regression, ridge regression, support vector machine, random forest, gradient boosting and extreme gradient boosting) to predict total in-hospital cost for admission for each condition. Our models had good predictive performance, with testing R-squared values of 0.701-0.750 (mean of 0.713) for CHF; 0.694-0.724 (mean 0.709) for COPD; and 0.615-0.729 (mean 0.694) for DKA. We identified important key features driving costs, including patient age, length of stay, number of procedures, and elective/nonelective admission. CONCLUSIONS: ML methods may be used to accurately predict costs and identify drivers of high cost for COPD exacerbations, CHF exacerbations and DKA. Overall, our findings may inform future studies that seek to decrease the underlying high patient costs for these conditions.
No takes yet. Share an insight, caveat, or question.
Arnold et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: